Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

和鉑醫藥控股有限公司

HBM Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

CHANGE OF EXECUTIVE DIRECTOR

The Board announces that:

1. Dr. Mai-Jing Liao has resigned as an executive Director of the Company with effect from 17 September 2021; and

2. Mr. Xiaoxiang Chen has been appointed as an executive Director of the Company with effect from 17 September 2021.

RESIGNATION OF EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Directors**") of HBM Holdings Limited (the "**Company**", and together with its subsidiaries, the "**Group**") announces that Dr. Mai-Jing Liao ("**Dr. Liao**") has tendered his resignation as an executive Director of the Company with effect from 17 September 2021 due to his personal reasons.

Dr. Liao has confirmed that he has no disagreement with the Board and there is no matter in respect of his resignation that needs to be brought to the attention of the shareholders of the Company (the "**Shareholders**") or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to take this opportunity to express its gratitude to Dr. Liao for his valuable contribution to the Company during his tenure of office.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Xiaoxiang Chen ("**Mr. Chen**") has been appointed as an executive Director of the Company with effect from 17 September 2021.

The biographical details of Mr. Chen are set out below:

Mr. Chen, aged 51, is the chief development officer of our Company. Mr. Chen joined Wyeth in February 1998 as a manager of clinical research and regulatory affairs, subsequently serving as director of clinical research in China from February 2001. He then served as the medical lead, acting as the global medical monitor for the chronic pain therapeutic area, from June 2008 until his departure from Wyeth in October 2009. From October 2009 to November 2015, Mr. Chen served as vice president and medical head of Greater China at Boehringer Ingelheim, and then as vice president and medical head of emerging markets from December 2015 until he departed from Boehringer Ingelheim in November 2017 to join our Company.

Mr. Chen received his bachelor's degree in clinical medicine in July 1993 and his master's degree in clinical medicine in July 1996, each from Nanjing Medical University in China. Mr. Chen has also been a deputy chief and a member of the Clinical Development Expert Committee of the Chinese Society of Clinical Oncology since September 2019.

Mr. Chen has entered into an appointment letter with the Company for a term of three years commencing from 17 September 2021, subject to (i) retirement from office and re-election at the next general meeting of the Company and (ii) retirement by rotation and re-election at least once every three years, in accordance with the articles of association of the Company and the corporate governance code as set out in Appendix 14 of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"). According to the terms of Mr. Chen's appointment, Mr. Chen will not receive any remuneration in connection with the performance of his duties as an executive Director under the appointment.

Save as disclosed above, as at the date of this announcement, Mr. Chen has confirmed that he does not hold (i) any other position with the Company or other members of the Group; (ii) any directorship in any other public companies with securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications.

As at the date of this announcement, Shuxin Biotech Limited ("**Shuxin**") and HBM Technology Limited ("**HBM Tech**") directly hold 33,034,400 and 8,125,000 ordinary shares of the Company (the "**Shares**"), respectively. Shuxin is held by Mr. Chen as to 85.39% and HBM Tech as to 14.61%. HBM Tech is wholly owned by Bright Swift Holdings Limited ("**Bright Swift**"), Bright Swift is in turn held by Mr. Chen as to 37.25%. Further, Mr. Chen is the sole director and controlling shareholder of Shuxin and HBM Tech and is therefore deemed to be interested for the purpose of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**") in the Shares held by Shuxin and HBM Tech. For further details, please refer to the Company's prospectus dated 30 November 2020.

Save as disclosed above, as at the date of this announcement, Mr. Chen has confirmed that he does not have any relationship with any Directors, senior management or substantial shareholders or controlling shareholders of the Company, or any interest in the shares of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, there is no other information that is required to be disclosed pursuant to any of the requirements under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules nor are there other matters that need to be brought to the attention of the Shareholders or the Stock Exchange relating to Mr. Chen's appointment.

The Board would like to express its warmest welcome to Mr. Chen on his appointment.

By order of the Board
HBM HOLDINGS LIMITED
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 17 September 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Mr. Xiaoxiang Chen as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.